Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAAA | Q02083 | 1/20 | 0.45 |
| ▸ | IDH1 | O75874 | 10/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.43 |
| ▸ | FAAH | O00519 | 1/20 | 0.42 |
| ▸ | PPARA | Q07869 | 2/20 | 0.41 |
| ▸ | IL6ST | P40189 | 1/20 | 0.40 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7306476 | 0.88 | NAAA (0.47) | NAAAIDH1HDAC1FAAHPPARA | |
| SCHEMBL9758542 | 0.86 | NAAA (0.46) | NAAAIDH1HDAC1FAAHPPARA | |
| SCHEMBL30812536 | 0.86 | NAAA (0.46) | NAAAIDH1HDAC1FAAHPPARA | |
| SCHEMBL4987701 | 0.86 | NAAA (0.46) | NAAAIDH1HDAC1FAAHPPARA | |
| SCHEMBL2501454 | 0.85 | NAAA (0.48) | NAAAIDH1FAAHPPARAIL6ST | |
| SCHEMBL2501460 | 0.85 | NAAA (0.48) | NAAAIDH1FAAHPPARAIL6ST | |
| SCHEMBL46356 | 0.85 | NAAA (0.48) | NAAAIDH1FAAHPPARAIL6ST | |
| SCHEMBL15586928 | 0.85 | NAAA (0.45) | NAAAIDH1HDAC1FAAHPPARA | |
| SCHEMBL548889 | 0.84 | NAAA (0.50) | NAAAIDH1HDAC1FAAHPPARA | |
| SCHEMBL1915646 | 0.84 | NAAA (0.47) | NAAAIDH1FAAHPPARAIL6ST |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170360747-A1 | USE OF ZILEUTON FOR THE TREATMENT OF NASAL POLYPS IN CYSTIC FIBROSIS PATIENTS | CORNERSTONE THERAPEUTICS INC. | 2017-12-21 | — | — | US | disclosed |
| EP-2959899-B1 | USE OF ZILEUTON FOR THE TREATMENT OF NASAL POLYPS IN CYSTIC FIBROSIS PATIENTS | CORNERSTONE THERAPEUTICS INC (US) | 2017-02-22 | — | — | EP | disclosed |
| EP-2959899-A1 | USE OF ZILEUTON FOR THE TREATMENT OF NASAL POLYPS IN CYSTIC FIBROSIS PATIENTS | Cornerstone Therapeutics Inc. (US) | 2015-12-30 | — | — | EP | disclosed |
| EP-2747762-B1 | USE OF ZILEUTON FOR THE TREATMENT OF NASAL POLYPS IN CYSTIC FIBROSIS PATIENTS | CORNERSTONE THERAPEUTICS INC (US) | 2015-07-01 | — | — | EP | disclosed |
| US-20140323446-A1 | USE OF ZILEUTON FOR THE TREATMENT OF NASAL POLYPS IN CYSTIC FIBROSIS PATIENTS | CORNERSTONE THERAPEUTICS INC. (US) | 2014-10-30 | — | — | US | disclosed |
| EP-2747762-A1 | USE OF ZILEUTON FOR THE TREATMENT OF NASAL POLYPS IN CYSTIC FIBROSIS PATIENTS | Cornerstone Therapeutics Inc. (US) | 2014-07-02 | — | — | EP | disclosed |
| WO-2013028880-A1 | USE OF ZILEUTON FOR THE TREATMENT OF NASAL POLYPS IN CYSTIC FIBROSIS PATIENTS | CORNERSTONE THERAPEUTICS INC. (US) | 2013-02-28 | — | — | WO | disclosed |
| US-20100273868-A1 | R-Zileuton for Use in Conditions Associated with Increased 5-Lipoxygenase and/or Leukotriene Activity (EG Asthma) | CORNERSTONE THERAPEUTICS INC. | 2010-10-28 | — | — | US | disclosed |
| EP-2114399-A2 | R-ZILEUTON FOR USE IN CONDITIONS ASSOCIATED WITH INCREASED 5-LIPOXYGENASE AND/OR LEUKOTRIENE ACTIVITY (EG ASTHMA) | Cornerstone Therapeutics Inc. (US) | 2009-11-11 | — | — | EP | disclosed |
| WO-2008085875-A2 | R-ZILEUTON FOR USE IN CONDITIONS ASSOCIATED WITH INCREASED 5-LIPOXYGENASE AND/OR LEUKOTRIENE ACTIVITY (EG ASTHMA) | CORNERSTONE THERAPEUTICS INC. (US) | 2008-07-17 | — | — | WO | disclosed |
| US-20060287338-A1 | Metalloproteinase inhibitor compounds | ASTRAZENECA AB (SE) | 2006-12-21 | — | — | US | disclosed |
| US-7122551-B2 | Metalloproteinase inhibitor compounds | ASTRAZENECA AB (SE) | 2006-10-17 | — | — | US | disclosed |
| CN-1247547-C | Piperidine and piperazine substituted N-hydroxyformamides as inhibitors of metalloproteinases | ASTRAZENECA AB (SE) | 2006-03-29 | — | — | CN | disclosed |
| US-20040176386-A1 | Compounds | ASTRAZENECA AB (SE) | 2004-09-09 | — | — | US | disclosed |
| US-6734183-B2 | USEFUL AS METALLOPROTEINASE INHIBITOR; PIPERAZINO-SULFONAMIDE OR PIPERIDINO-SULFONAMIDE COMPOUND | ASTRAZENECA AB (SE) | 2004-05-11 | — | — | US | disclosed |
| CN-1418197-A | Piperidine and piperazine substituted N-hydroxycarboxamides as metalloproteinase inhibitors | ASTRAZENECA AB (SE) | 2003-05-14 | — | — | CN | disclosed |
| EP-1261590-A1 | PIPERIDINE- AND PIPERAZINE SUBSTITUTED N-HYDROXYFORMAMIDES AS INHIBITORS OF METALLOPROTEINASES | AstraZeneca AB (SE) | 2002-12-04 | — | — | EP | disclosed |
| US-20020022628-A1 | Compounds | ASTRAZENECA AB (SE) | 2002-02-21 | — | — | US | disclosed |
| WO-2001062742-A1 | PIPERIDINE- AND PIPERAZINE SUBSTITUTED N-HYDROXYFORMAMIDES AS INHIBITORS OF METALLOPROTEINASES | ASTRAZENECA AB (SE) | 2001-08-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020022628-A1 | Compounds | MMP13, MMP11, MMP3 | NAAA 1907/4885IDH1 1143/4885HDAC1 93/4885 |
| US-20170360747-A1 | USE OF ZILEUTON FOR THE TREATMENT OF NASAL POLYPS IN CYSTIC FIBROSIS PATIENTS | CFTR, CCL11, ADCYAP1R1 | NAAA 1980/4885IDH1 3532/4885HDAC1 354/4885 |
| US-20060287338-A1 | Metalloproteinase inhibitor compounds | TIMP3, MMP2, MMP13 | NAAA 1165/4885IDH1 1210/4885HDAC1 147/4885 |
| US-20040176386-A1 | Compounds | MMP13, MMP11, MMP3 | NAAA 1907/4885IDH1 1143/4885HDAC1 93/4885 |
| US-20100273868-A1 | R-Zileuton for Use in Conditions Associated with Increased 5-Lipoxygenase and/or Leukotriene Activity (EG Asthma) | ALOX5, ALOX15, LTA4H | NAAA 1542/4885IDH1 4573/4885HDAC1 872/4885 |
| US-20140323446-A1 | USE OF ZILEUTON FOR THE TREATMENT OF NASAL POLYPS IN CYSTIC FIBROSIS PATIENTS | CFTR, CCL11, ADCYAP1R1 | NAAA 1980/4885IDH1 3532/4885HDAC1 354/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.